MELBOURNE, Australia, June 16, 2025 - Amplia Therapeutics Limited (ASX: ATX) has announced new data from its ongoing ACCENT clinical trial, which is evaluating the company's FAK inhibitor, narmafotinib, in combination with standard-of-care chemotherapies gemcitabine and Abraxane® for advanced pancreatic cancer. The trial has recorded a notable achievement with a patient exhibiting a pathological complete response (pCR), an uncommon occurrence in patients with metastatic pancreatic cancer. This result marks a significant milestone for the ACCENT trial, which continues to investigate the potential benefits of narmafotinib in treating advanced pancreatic cancer. Further details on the trial's findings and implications will be shared as the study progresses.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.